C
Curtis Cooper
Researcher at University of Ottawa
Publications - 315
Citations - 11322
Curtis Cooper is an academic researcher from University of Ottawa. The author has contributed to research in topics: Hepatitis C & Population. The author has an hindex of 45, co-authored 275 publications receiving 10139 citations. Previous affiliations of Curtis Cooper include St. Francis Xavier University & Ottawa Hospital.
Papers
More filters
Journal ArticleDOI
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
Edward J Mills,Jean B. Nachega,Jean B. Nachega,Iain Buchan,James Orbinski,Amir Attaran,Sonal Singh,Sonal Singh,Beth Rachlis,Ping Wu,Curtis Cooper,Lehana Thabane,Kumanan Wilson,Gordon H. Guyatt,David R. Bangsberg +14 more
TL;DR: The findings indicate that favorable levels of adherence, much of which was assessed via patient self-report, can be achieved in sub-Saharan African settings and that adherence remains a concern in North America.
Journal ArticleDOI
Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators
Edward J Mills,Jean B. Nachega,David R. Bangsberg,Sonal Singh,Beth Rachlis,Ping-ping Wu,Kumanan Wilson,Iain Buchan,Christopher J. Gill,Curtis Cooper +9 more
TL;DR: Important barriers to adherence are consistent across multiple settings and countries, and Clinicians should use this information to engage in open discussion with patients to promote adherence and identify barriers and facilitators within their own populations.
Journal ArticleDOI
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci,David E. Bernstein,Jacob Lalezari,Daniel E. Cohen,Yan Luo,Curtis Cooper,Edward Tam,Rui Tato Marinho,Naoky Tsai,A. Nyberg,Terry Box,Ziad Younes,Pedram Enayati,Sinikka Green,Yaacov Baruch,Bal R. Bhandari,Florin Alexandru Caruntu,Thomas Sepe,Vladimir Chulanov,Ewa Janczewska,Giuliano Rizzardini,J. Gervain,Ramon Planas,Christophe Moreno,Tarek Hassanein,Wangang Xie,M. King,Thomas Podsadecki,K. Rajender Reddy +28 more
TL;DR: Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was associated with high rates of sustained virologic response among previously untreated patients with HCV genotype 1 infection.
Journal ArticleDOI
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie,Curtis Cooper,Michael S. Saag,Kimberly A. Workowski,Peter Ruane,William J. Towner,Kristen M. Marks,Anne F Luetkemeyer,Rachel Baden,Rachel Baden,Paul E. Sax,E.J. Gane,Jorge Santana-Bagur,Luisa M. Stamm,Jenny C. Yang,Polina German,Hadas Dvory-Sobol,Liyun Ni,Phillip S. Pang,John G. McHutchison,Catherine A.M. Stedman,Javier O Morales-Ramirez,Norbert Bräu,Norbert Bräu,Dushyantha Jayaweera,Amy E. Colson,Pablo Tebas,David Wong,Douglas T. Dieterich,Mark S. Sulkowski +29 more
TL;DR: Ledipasvir and sofosbuvir as a single fixed-dose combination for 12 weeks provided high rates of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4.
Journal ArticleDOI
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
Markus Cornberg,Homie Razavi,A. Alberti,Enos Bernasconi,Maria Buti,Curtis Cooper,Olav Dalgard,John F. Dillion,Robert Flisiak,Xavier Forns,Sona Frankova,Adrian Goldis,Ioannis Goulis,Waldemar Halota,Béla Hunyady,Martin Lagging,Angela Largen,Michael Makara,Spilios Manolakopoulos,Patrick Marcellin,Rui Tato Marinho,Stanislas Pol,Thierry Poynard,Massimo Puoti,Olga Sagalova,Scott Sibbel,Krzysztof Simon,Carolyn Wallace,Kendra A. Young,Cihan Yurdaydin,Eli Zuckerman,Francesco Negro,Stefan Zeuzem +32 more
TL;DR: A comprehensive review of the literature was used to gather country‐specific data on risk factors, prevalence, number of diagnosed individuals and genotype distribution of the hepatitis C virus (HCV) infection in selected European countries, Canada and Israel.